Indian Drug Makers Urge FDA To Conduct Virtual Facility Inspections

By Kelly Lienhard / April 27, 2020 at 12:53 PM
The Indian Pharmaceutical Alliance is urging FDA to conduct desk reviews, including virtual inspections, of certain drug manufacturing facilities in India for the duration of the COVID-19 pandemic as a way to proceed with facility inspections and mitigate future drug shortages. In a Monday (April 20) letter to FDA drug center director Janet Woodcock, the alliance’s secretary general, Sudarshan Jain, said he’s concerned the indefinite postponement of FDA foreign inspections could lead to disruptions in America’s drug supply. Jain encouraged...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.